PREVENTIVE AND/OR THERAPEUTIC AGENT FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME Russian patent published in 2025 - IPC A61K31/343 A61K31/416 A61K31/4184 A61K31/423 A61P13/08 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to pharmaceutical industry, namely to use of mPGES-1 inhibitor for preparing a drug for preventing and/or treating chronic prostatitis/chronic pelvic pain syndrome. Disclosed is the use of the mPGES-1 inhibitor for the manufacture of a medicinal agent for preventing and/or treating chronic prostatitis/chronic pelvic pain syndrome, where the mPGES-1 inhibitor is: compound selected from a group consisting of N-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide and N-(3-chloro-2-methylphenyl)-2-[1-(trifluoromethyl)cyclopropyl]-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide or a tautomer of a compound, or a pharmaceutically acceptable salt thereof; N-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide 4-methylbenzene sulphonate; N-(3-chloro-2-methylphenyl)-2-[1-(trifluoromethyl)cyclopropyl]-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide.

EFFECT: described above mPGES-1 inhibitors are effective for preparing a drug for preventing and/or treating chronic prostatitis/chronic pelvic pain syndrome.

3 cl, 1 dwg, 1 tbl, 8 ex